SEHK:2566Biotechs
Stable 10.6% Margin At Hangzhou Jiuyuan Genetic Biopharmaceutical Reinforces Bullish Valuation Narratives
Hangzhou Jiuyuan Genetic Biopharmaceutical (SEHK:2566) has put fresh FY 2025 numbers on the table, with first half revenue of C¥638.8 million and basic EPS of C¥0.37 setting the tone for how the year is shaping up. Over recent halves the company has seen revenue move from C¥702.4 million and EPS of C¥0.53 in 1H 2024 to C¥666.8 million and EPS of C¥0.16 in 2H 2024, giving investors a clear view of how the current run rate compares with recent history. With trailing 12 month net profit margins...